Infliximab is a chimeric monoclonal antibody against anti-tumour necrosis factor alpha that
has changed the management of inflammatory bowel diseases. Our review describes its …

Infliximab is a monoclonal chimeric antibody, with high affinity and specificity for tumour
necrosis factor alpha (TNFalpha) that plays a central role in the pathogenesis of immune …

The advent of infliximab a decade ago has drastically changed the treatment paradigm for
patients with inflammatory bowel diseases (IBD). Controlled evidence supports the use of …

Opinion statement Crohn's disease (CD) and ulcerative colitis (UC) are chronic and often
debilitating inflammatory bowel diseases (IBD) without medical cures. Despite the existence …

Infliximab, the chimeric monoclonal IgG1 antibody to tumour necrosis factor, is indicated for
refractory luminal and fistulizing Crohn's disease and extra‐intestinal manifestations of …

Infliximab was first introduced in Europe in 1999 for Crohn's disease. During the following
decade major progress was made in the understanding of the pathophysiology of …

Background: Infliximab, a chimeric anti-tumour necrosis factor monoclonal antibody with
potent anti-inflammatory effects, represents an effective treatment option in patients with …

In this large series, the investigators evaluated the short-and long-term safety of infliximab in
patients with Crohn's disease. Using pharmacy records, 500 patients with Crohn's disease …

Infliximab (IFX) is an effective treatment for inducing and maintaining response in Crohn's
disease and ulcerative colitis patients. Some patients present lack of response or loss of …

Background: Infliximab is a chimeric immunoglobulin G1κ monoclonal antibody that binds
with high affinity and specificity to the soluble form of tumor necrosis factor (TNF)-α …